Is celastrol worth trying or putting into the itp

#1
#2

Celastrol (tripterine): geroscience evidence summary

Bottom line: Celastrol has genuinely interesting healthspan and mechanistic data — as a leptin sensitizer, anti-inflammatory, exercise/proteostasis mimetic, and more recently a senolytic — but hard lifespan-extension evidence is confined to invertebrates and one under-powered mouse signal. Its clinical development is real but aimed at obesity, not aging, and a narrow toxic therapeutic window is the dominant barrier. I’d rate it “mechanistically promising, translationally unproven.”

What it is

A pentacyclic triterpenoid (quinone methide) from Tripterygium wilfordii (“thunder god vine”). It is a promiscuous, thiol-reactive electrophile that hits many targets, which explains both its broad activity and its toxicity.

Lifespan data (where the actual longevity evidence sits)

  • C. elegans: extends lifespan ~27.6% at 10 ÎĽM, with restored muscle integrity and mitochondrial morphology — but worm hits are weak predictors of mammalian effect.
  • Mice (ITP-style testing): celastrol showed only a trend toward extended lifespan in both sexes; the study was under-powered to reach significance per sex. This is the honest ceiling of current mammalian survival data.
  • Drosophila: a 2026 senolytic study reported extended median and maximum lifespan.

So: reproducible invertebrate lifespan extension, no confirmed mammalian lifespan extension.

Healthspan / mechanism (the strongest body of evidence)

  • Leptin sensitizer (metabolic aging): the landmark finding (Liu et al., Cell 2015) — up to ~45% weight loss in diet-induced obese, hyperleptinemic mice by restoring leptin sensitivity; young/lean animals are largely unaffected, consistent with an age/obesity-selective effect.
  • HSF1–PGC1α axis / “exercise mimetic”: drives energy expenditure independent of food intake, boosts mitochondrial biogenesis; identified in silico as mimicking a PGC-1α/exercise gene signature and improving sarcopenia and mitochondrial function.
  • Proteostasis & inflammation: HSF1/heat-shock activation, NF-ÎşB inhibition, AMPK/ULK1-driven autophagy, and suppression of inflammatory (JAK/STAT, MAPK, TLR) signaling — all hallmark-of-aging-relevant pathways.
  • Senolytic (2026): disrupts an Hsc70–Bim–CHIP complex to stabilize Bim and kill senescent cells, reportedly out-performing ABT-263 and fisetin in potency, reducing organ fibrosis and intestinal senescence — with a prodrug strategy proposed to widen the safety margin.

Human clinical evidence

Limited and metabolic, not gerotherapeutic. ERX Pharmaceuticals’ ERX-1000 (a celastrol-based leptin sensitizer) completed a first-in-human Phase 1 (double-blind, placebo-controlled) showing generally well-tolerated, dose-responsive weight loss over 4 weeks. A Phase 2A obesity trial (NCT07570758) is planned for ~2026–2027. There are no human aging/longevity endpoint trials, and human data for liver or other disease indications remain very sparse.

The key limitation

A narrow therapeutic window dominates translation: dose-dependent hepatotoxicity, nephrotoxicity, cardiotoxicity, hematopoietic and reproductive toxicity, GI irritation, plus poor oral bioavailability (~17%). Effective doses sit close to toxic ones — which is exactly why current clinical translation relies on analogues, prodrugs, and nanoformulations rather than raw celastrol.

Geroscientist’s verdict

Celastrol engages an unusually broad set of aging hallmarks (proteostasis, chronic inflammation, senescence, mitochondrial/metabolic decline) and has real, reproducible healthspan effects in rodent metabolic aging plus early positive human obesity data. But it should not yet be presented as a proven longevity drug: mammalian lifespan extension is unconfirmed, and safety is the rate-limiting problem. The most credible near-term path is an engineered derivative (e.g., ERX-1000 or senolytic prodrugs) rather than the parent compound.

Sources:

1 Like